Trial Profile

A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amivantamab (Primary) ; Carboplatin (Primary) ; Lazertinib (Primary) ; Pemetrexed (Primary)
Indications Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Acronyms PALOMA-2
Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

15 Oct 2025 According to Johnson & Johnson media release, data from this study will be presented at the European Society for Medical Oncology (ESMO) 2025 Congress.
14 Oct 2025 Planned number of patients changed from 521 to 520.
23 May 2025 Planned primary completion date changed from 31 Oct 2025 to 17 Aug 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com